-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 20, Xiansheng Zaiming announced that the PD-L1 antibody drug for subcutaneous administration in collaboration with Corning Jerry Biopharmaceuticals and Siludi Pharmaceuticals for the treatment of advanced solid tumors in adults with high microsatellites was reviewed and approved by the China Drug Administration and changed from conditional approval to routine approval; at the same time, the additional 600 mg dosing plan every three weeks was also approved.
Share
Listen to the news
On November 20, Xiansheng Zaiming announced that the PD-L1 antibody drug for subcutaneous administration in collaboration with Corning Jerry Biopharmaceuticals and Siludi Pharmaceuticals for the treatment of advanced solid tumors in adults with high microsatellites was reviewed and approved by the China Drug Administration and changed from conditional approval to routine approval; at the same time, the additional 600 mg dosing plan every three weeks was also approved.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending